List of works - Julia Wilkerson

A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide

scientific article published on 01 August 2019

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes

scientific article published on 26 January 2019

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

scientific article published on 17 February 2012

Bevacizumab and breast cancer: the E2100 outlier

scientific article published on 01 December 2010

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis

scientific article published on 25 June 2015

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example

scientific article

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

scientific article published on 12 December 2016

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

scientific article

Hazard ratios in cancer clinical trials--a primer.

scientific article published on 31 January 2012

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies ⬇️

scientific article published on January 18, 2013

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin

scientific article

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

scientific article

Mitosis is not a key target of microtubule agents in patient tumors.

scientific article published in February 2011

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma

scientific article published on 3 June 2015

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

scientific article published on September 2009

Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

scientific article published on September 2009

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

scientific article published on 07 February 2013

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer

scientific article published on July 2016

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer

scientific article published on January 2014

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

scientific article published in September 2014

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.

scientific article published on 5 December 2014

List of works by Julia Wilkerson

A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Bevacizumab and breast cancer: the E2100 outlier

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Hazard ratios in cancer clinical trials--a primer.

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies ⬇️

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

Mitosis is not a key target of microtubule agents in patient tumors.

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.